Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy

用于卵巢癌治疗的抗血管和细胞毒性纳米颗粒制剂

• 批准号: 10227030
• 负责人: JOHN A MARTIGNETTI
• 金额: $ 33.06万
• 依托单位: BROOKLYN COLLEGE
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10227030
• 关键词: Adverse effects; Amino Acids; Angiogenesis Inhibitors; Antineoplastic Agents; Biodistribution; Biological; Biological Assay; Blood; Blood Vessels; Cancer Patient; Cancer Relapse; Cancer cell line; Cell Proliferation; Cell Survival; Cells; Clinic; Clinical; Combretastatin; Confocal Microscopy; Coupled; DNA Adducts; DNA Damage; DNA Repair; Data; Diagnosis; Diagnostic; Disease; Dose; Dose-Limiting; Drug resistance; Effectiveness; Encapsulated; Endothelial Cells; Endothelium; Ensure; Evaluation; Exhibits; FDA approved; Fluorescence; Formulation; Generations; Glycolates; Goals; Half-Life; Histologic; Histology; Immune system; Immunochemistry; In Vitro; Integrin alphaVbeta3; Intraperitoneal Injections; Kinetics; Ligands; Liposomes; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of ovary; Measures; Microscopic; Microscopy; Minor; Modification; Molecular; Monoclonal Antibodies; Near-infrared optical imaging; Ovarian; Patients; Peptides; Peripheral Nervous System; Permeability; Pharmaceutical Preparations; Pharmacology; Platinum; Polymers; Progression-Free Survivals; Property; Resistance; Route; Surface; System; Techniques; Testing; Therapeutic; Tissue imaging; Toxic effect; Treatment Efficacy; Treatment Protocols; Treatment outcome; United States; Visualization; Woman; Work; base; bevacizumab; bioluminescence imaging; cancer cell; cancer therapy; chemotherapy; clinical investigation; cytotoxic; design; dosage; drug efficacy; drug release profile; female reproductive system; flexibility; fluorophore; imaging modality; improved; in vitro testing; in vivo; in vivo imaging; mortality; mouse model; nanoparticle; nanoparticle delivery; nanotherapy; nephrotoxicity; non-invasive imaging; non-invasive optical imaging; novel; pre-clinical; receptor mediated endocytosis; reproductive outcome; systemic toxicity; targeted agent; targeted delivery; targeted treatment; theranostics; therapy outcome; treatment strategy; tumor; tumor growth; uptake

Ovarian cancer (OC) has the highest mortality rate of all cancers of the female reproductive system and outcomes have not changed over the past four decades. This year, over 20,000 women will be diagnosed with OC in the United States more than 14,000 women will die from this disease. Platinum-based therapy is the main therapeutic option for OC patients and ultimately, systemic toxicity limits the dosage given and this, in part, limits its effectiveness. To overcome this therapeutic roadblock, alternative routes of administration have been sought and include the practically difficult intraperitoneal (IP) injection, and more recently, the emerging strategy of combining Pt (II) chemotherapy with tumor vasculature-targeting agents. The overarching goal of this study is to develop a nanoparticle (NP)-based therapy for targeted delivery of high dose Pt (II) and a vascular disrupting agent directly to cancer cells and endothelium, to enhance treatment outcomes. As proof- of-principle, we have chosen combretastatin CA4 as the vascular targeting agent. Our proposal explores a second generation, slow releasing polymer NP platform, with poly(lactic-co-glycolic) (PLGA) acid core encapsulating Pt (II) and CA4. The NP’s coating is comprised of a RGDFFF peptide that stabilizes the NP and simultaneously serves as a targeting ligand to αvβ3 integrin via its RGD moiety. The PLGA is FDA-approved and amino acids of the peptide have Generally Regarded As Safe (GRAS) status. The NP is completely biodegradable. Encapsulation of Pt (II) and CA4 will reduce systemic toxicity and allow us to explore the use of effectively higher dosages than currently feasible. Upon the NP’s accumulation in the tumor interstitium, via enhanced permeability and retention (EPR) effects, the cellular NPs uptake will be enhanced via receptor- mediated endocytosis. The effect of the cytotoxic activity of Pt (II) and CA4 towards cancer cells and the tumor’s vasculature, will be measured through therapeutic outcomes. A small percentage of near infrared fluorophore (NIRF) will be incorporated into the NP’s coating to enable noninvasive optical imaging. The combination of therapeutic and diagnostic features will transform the NP into a “theranostic” platform. In vitro studies will include evaluation of NPs targeting to cancer cells, their biological activity, and compatibility with the immune system. In vivo studies will focus on the assessment of NPs pharmacologic parameters, tumor targeting, tolerability, and, finally, therapeutic efficacy. Combined in vitro and in vivo studies will employ microscopy, immunochemistry, and histology, to define the best NP-based treatment regimen resulting in therapeutic outcomes rivaling free drug routines currently used in the clinic. Thus, the proposed specific aims are: Aim 1: Synthesize and characterize an RGDFFF-coated NP platform for targeting, visualizing and treating ovarian cancer. Aim 2: Test targeting efficacy and therapeutic potential of CA4-NPs and Pt-NPs in vitro. Aim 3: Study the biodistribution and targeted ‘trapping’ of NPs in a preclinical OC mouse model via in vivo imaging. Aim 4: Conduct a therapy study wherein CA4-NPs and Pt-NPs, are applied to a preclinical OC mouse model.

卵巢癌(OC)在所有女性生殖系统癌症中死亡率最高， 在过去的40年里，结果没有改变。今年，超过20,000名妇女将被诊断出患有 在美国，超过14,000名妇女将死于这种疾病。以铂为基础的疗法是 OC患者的主要治疗选择，最终，全身毒性限制了给予的剂量，这在 部分，限制了它的有效性。为了克服这一治疗障碍，替代给药途径有 一直在寻求，包括实际上困难的腹膜内注射，以及最近出现的 铂(II)化疗与肿瘤血管靶向药物联合的策略。的首要目标是 这项研究旨在开发一种基于纳米颗粒(NP)的治疗方法，用于靶向传递高剂量的铂(II)和 血管干扰剂直接作用于癌细胞和血管内皮细胞，提高治疗效果。作为证据- 原则上，我们选择了康泰素CA4作为血管靶向剂。我们的建议探索了一个 第二代缓释聚合物NP平台，以聚(乳酸-乙醇酸)(PLGA)为核心 包覆铂(II)和钙离子。NP的涂层由稳定NP的RGDFFF肽和 同时通过其RGD端作为αvβ3整合素的靶向配体。PLGA是FDA批准的 而氨基酸一般被认为是安全的(GRAS)状态。NP完全是 可生物降解的。包裹铂(II)和钙离子将减少全身毒性，并使我们能够探索使用 有效地比目前可行的剂量更高。根据NP在肿瘤间质中的积聚，通过 增强通透性和滞留(EPR)效应，细胞对NPs的摄取将通过受体- 介导的内吞作用。铂(II)和钙离子对癌细胞的细胞毒作用及其机制 肿瘤的血管系统，将通过治疗结果进行测量。一小部分近红外 荧光体(NIRF)将被结合到NP的涂层中，以实现非侵入性光学成像。这个 治疗和诊断功能的结合将把NP转变为一个“治疗”平台。离体 研究将包括评估以癌细胞为靶点的纳米粒，它们的生物活性，以及与 免疫系统。体内研究将集中在评估NPs的药理参数、肿瘤 靶向性、耐受性，最后是治疗效果。体外和体内相结合的研究将使用 显微镜、免疫化学和组织学，以确定基于NP的最佳治疗方案，从而导致 治疗效果可与目前临床上使用的免费药物相媲美。因此，拟议的具体目标 包括： 目的1：合成和表征一种靶向、可视化和治疗用的RGDFFF包衣NP平台 卵巢癌。目的2：检测钙纳米粒和铂纳米粒的体外靶向效应和治疗潜力。 目标3： 通过活体成像研究NPs在临床前期OC小鼠模型中的生物分布和靶向‘捕获’。 目的：将Ca4纳米粒子和铂纳米粒子应用于临床前OC小鼠模型，进行治疗研究。